First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.

Mingzhi Zhang,Lin Yang,Xiaorui Fu,Lei Zhang,Huimin Meng,Ling Li,Xin Li,Xinhua Wang,Zhenchang Sun,Hui Yu,Zhaoming Li,Feifei Nan,Yu Chang,Zhiyuan Zhou,Jiaqin Yan,Jiwei Li,Min Wang,Fengtao You,Yu-Sheng Chen,Bozhen Zhang

First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.

2020

Mingzhi Zhang
Lin Yang
Xiaorui Fu
Lei Zhang
Huimin Meng
Ling Li
Xin Li
Xinhua Wang
Zhenchang Sun
Hui Yu
Zhaoming Li
Feifei Nan
Yu Chang
Zhiyuan Zhou
Jiaqin Yan
Jiwei Li
Min Wang
Fengtao You
Yu-Sheng Chen
Bozhen Zhang

3026Background: CD7 represents a potential target for T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL). We developed CD7 nanobody derived chimeric antigen receptor T-cells (CD7-CART), and...

Keywords:

Oncology
Cart
Internal medicine
first in human
Clinical trial
Pathology
Acute lymphoblastic leukemia-lymphoma
relapsed refractory
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations